Nash Hit primary endpoint on open label 350Mg N
Post# of 148158
(Total Views: 620)
Posted On: 01/05/2022 11:47:39 AM
Nash
Hit primary endpoint on open label 350Mg Nash study.
“The leronlimab 350 mg dose versus placebo comparison for the primary endpoint PDFF was statistically significant.”
Almost hit secondary endpoint @ 350Mg.
“Leronlimab compared to placebo also reached near significance for the secondary endpoint cT1”
The point of this Open Label study, imo, was for dose justification and to see which biomarkers / genetics for certain people to understand why they need 700Mg.
“We are in the process of analyzing biomarker data including CCR5 haplotype information to better understand responder rates and mechanism of action.”
With the 700Mg coming out anyday, with same end points, & them saying they would aggressively seek partnership.
This is likely part of the aggressiveness. A PR that basically tells Longs it works, meanwhile liars say otherwise.
The PR is clear:
We had amazing results at 14 weeks, where most trials take 24-32 weeks. Even at half power 350Mg, we are doing pretty damn amazing.
The BLINDED 700Mg trial results will be market moving, in my humble opinion.
Hit primary endpoint on open label 350Mg Nash study.
“The leronlimab 350 mg dose versus placebo comparison for the primary endpoint PDFF was statistically significant.”
Almost hit secondary endpoint @ 350Mg.
“Leronlimab compared to placebo also reached near significance for the secondary endpoint cT1”
The point of this Open Label study, imo, was for dose justification and to see which biomarkers / genetics for certain people to understand why they need 700Mg.
“We are in the process of analyzing biomarker data including CCR5 haplotype information to better understand responder rates and mechanism of action.”
With the 700Mg coming out anyday, with same end points, & them saying they would aggressively seek partnership.
This is likely part of the aggressiveness. A PR that basically tells Longs it works, meanwhile liars say otherwise.
The PR is clear:
We had amazing results at 14 weeks, where most trials take 24-32 weeks. Even at half power 350Mg, we are doing pretty damn amazing.
The BLINDED 700Mg trial results will be market moving, in my humble opinion.
(14)
(0)CytoDyn Inc (CYDY) Stock Research Links
Scroll down for more posts ▼